Cell Pathways

Other

W Joseph Thompson

Han Li

Hector W Alila

Li Liu

Rifat Pamukcu

Gary A Piazza

Keith A Earle

Clark M Whitehead

Robert E Bellet

I Bernard Weinstein

John R Fetter

Bing Zhu

Jae-Won Soh

This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an inhibitor of human epidermal growth factor receptor tyrosine kinase and a cGMP-specific phosphodiesterase inhibitor.

Method for treating a patient with neoplasia using Iressa

This invention provides a method to identify compounds potentially useful for the treatment and prevention of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with its ability to elevate JNK kinase activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibition, an ability to elevate JNK kinase activity, growth inhibition and apoptosis induction are desirable for the treatment of neoplasia.

Method for screening compounds for the treatment of neoplasia

A method of treating renal cell carcinoma in a mammal with that disease comprising administering to the mammal a physiologically effective amount of an inhibitor of PDE10.

Methods for treatment of renal cell carcinoma

Substituted condensation products of -benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of type I diabetes.

Methods for treatment of type I diabetes

Substituted condensation products of N-benzyl-3-indenylacetamides with heterocyclic aldehydes and other such inhibitors are useful for the treatment of cystic fibrosis.

Methods for treatment of cystic fibrosis

A method for identifying compounds useful for the treatment of neoplasia involves acertaining whether such compounds exhibit an ability to inhibit a PDE that is characterized by cGMP specificity, cooperative kinetic behavior and insensitivity to phosphorylation.

Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia

A method for selecting compounds for the treatment of neoplasia includes assessing whether the compounds cause an increase in PKG activity in the neoplasia of interest.

Method for selecting compounds for inhibition of neoplastic lesions

This invention provides a method to identify compounds potentially useful for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.

Growing community of inventors

Doylestown, PA, United States of America

W Joseph Thompson